In CLL, evidence suggests the presence of multiple clones of leukemia-reactive CD4+ and CD8+ T cells in patients, indicating that a vaccine approach using whole tumor cells may be more effective than one targeting a single antigen. The gene discussed is CD8A; the disease is neoplasm.